GA101 P329GLALA, a variant of obinutuzumab with abolished ADCC, ADCP and CDC function but retained cell death induction, is as efficient as rituximab in B-cell depletion and antitumor activity

Bibliographic Details
Main Authors:	Sylvia Herter, Frank Herting, Gunter Muth, Erwin van Puijenbroek, Tilman Schlothauer, Claudia Ferrara, Kevin Brady, Sabine Lang, Marina Bacac, Ekkehard Mössner, Pablo Umana, Christian Klein
Format:	Article
Language:	English
Published:	Ferrata Storti Foundation 2018-02-01
Series:	Haematologica
Online Access:	https://haematologica.org/article/view/8369

Internet